The shares of Teva Pharmaceutical Industries Limited have increased by more than 17.84% this year alone. The shares recently went down by -1.06% or -$0.24 and now trades at $22.33. The shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), has slumped by -5.90% year to date as of 08/09/2018. The shares currently trade at $2.71 and have been able to report a change of 5.45% over the past one week.
The stock of Teva Pharmaceutical Industries Limited and Achillion Pharmaceuticals, Inc. were two of the most active stocks on Thursday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.Next 5Y EPS Growth: -9.94% versus 17.58%
When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. Analysts have predicted that TEVA will grow it’s earning at a -9.94% annual rate in the next 5 years. This is in contrast to ACHN which will have a positive growth at a 17.58% annual rate. This means that the higher growth rate of ACHN implies a greater potential for capital appreciation over the years.Profitability and Returns
Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. These figures suggest that ACHN ventures generate a higher ROI than that of TEVA.Liquidity and Financial Risk
The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for TEVA is 1.00 and that of ACHN is 38.00. This implies that it is easier for TEVA to cover its immediate obligations over the next 12 months than ACHN. The debt ratio of TEVA is 2.06 compared to 0.00 for ACHN. TEVA can be able to settle its long-term debts and thus is a lower financial risk than ACHN.Valuation
TEVA currently trades at a forward P/E of 7.90, a P/B of 1.52, and a P/S of 1.13 while ACHN trades at a P/B of 1.22, This means that looking at the earnings, book values and sales basis, TEVA is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.Analyst Price Targets and Opinions
The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of TEVA is currently at a 7.67% to its one-year price target of 20.74. Looking at its rival pricing, ACHN is at a -51.43% relative to its price target of 5.58.
When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), TEVA is given a 3.00 while 2.00 placed for ACHN. This means that analysts are more bullish on the outlook for TEVA stocks.Insider Activity and Investor Sentiment
Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for TEVA is 3.95 while that of ACHN is just 6.26. This means that analysts are more bullish on the forecast for TEVA stock.
The stock of Teva Pharmaceutical Industries Limited defeats that of Achillion Pharmaceuticals, Inc. when the two are compared, with TEVA taking 3 out of the total factors that were been considered. TEVA happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, TEVA is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for TEVA is better on when it is viewed on short interest.